Translating scientific findings, novel medical devices, new diagnostics and therapies for infertility
There is potential to shorten the time to healthy live birth, improve patient care and facilitate decision-making through the development of new technologies and services.
Merck KGaA, Darmstadt, Germany recognizes infertility as a disease and our mission is to maximise the probability of healthy live birth in the shortest time possible.
We believe there are FOUR key elements that make up the innovation process:
- IP management
The questions that arise are: What areas of research will produce the most interesting projects and how can we enable technologies? Merck KGaA, Darmstadt, Germany has identified certain areas of interest that the MIP is trying to address.
The MIP embraces relevant key enabling technologies, as listed below, to overcome clinical fertility restraint and make diagnostic and therapeutic procedures robust, rapid and precise.
The main objective is to translate scientific findings, novel medical devices, new diagnostics and therapies, with support from enabling technologies.
Key Areas of Interest 2020-2021
Merck KGaA, Darmstadt, Germany has identified priority unmet medical needs in fertility treatment and innovation. These include:
- Therapies to improve endometrial receptivity and implantation potential via intrauterine administration or other innovative methods
- Technologies and treatments to improve oocyte quality and quantity for patients with diminished ovarian reserve
- Approaches to diagnose, select, and enhance viability and motility of sperm for IVF/ICSI
The MIP will be a Collaborative Network to support discussion and exchange of ideas on unmet medical needs.
This network will engage clinicians, researchers, embryologists and engineers in testing approaches to help develop research and technologies into practice. MIP's main TSP, the University of Naples Federico II, will support collaborations and drive forward fertility innovation, by offering access to the following services:
- Implant- or tissue-on-chip